DK3050563T3 - Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af hudsygdomme og -tilstande - Google Patents
Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af hudsygdomme og -tilstande Download PDFInfo
- Publication number
- DK3050563T3 DK3050563T3 DK16161920.0T DK16161920T DK3050563T3 DK 3050563 T3 DK3050563 T3 DK 3050563T3 DK 16161920 T DK16161920 T DK 16161920T DK 3050563 T3 DK3050563 T3 DK 3050563T3
- Authority
- DK
- Denmark
- Prior art keywords
- methyl
- ethyl
- imidazol
- benzyl ester
- acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (2)
1. Sammensætning til anvendelse i behandling af hudsygdomme og hudtilstande hos en menneskelig patient med behov for sådan behandling ved topikal dermatologisk anvendelse af en terapeutisk effektiv mængde af nævnte sammensætning omfattende en forbindelse ifølge formel I, dets individuelle enantiomerer, dets individuelle diastereoisomerer, dets hydrater, dets solvater, dets krystalformer, dets individuelle tautomerer eller et farmaceutisk acceptabelt salt deraf, O R2 R1 R3 Formel I hvor R1 er H eller C1-3 alkyl; R2 er H eller C1-3 alkyl; R3 er H, Ci-10 alkyl, heterocykel eller aryl; og R er Ci-10 alkyl, heterocykel eller aryl, hvor "alkyl" betyder en mættet monovalent alkandel, som har lige eller forgrenede alkandele eller kombinationer deraf, som eventuelt kan substitueres af aminogrupper, arylgrupper, halogener, og et methylen (-CH2-) kan erstattes af carbonyl, -NH-, carboxyl, amid, svovl eller af oxygen, og "heterocykel" betyder en aromatisk eller ikke-aromatisk 5- til 10-leddet monocyklisk eller bicyklisk ring, som indeholder mindst ét heteroatom valgt fra O eller N eller S eller kombinationer deraf, som afbryder den carbocykliske ringstruktur, som eventuelt kan substitueres af C1-6 alkyl,
amino, halogen, -O(Ci-e alkyl), - OC(O)(Ci-e alkyl), -C(O)O(Ci-e alkyl), -NHC(O)(Ci-e alkyl), -C(O)NH(Ci-e alkyl), - S(Ci-e alkyl) grupper, og "aryl" betyder en organisk del afledt fra et aromatisk carbonhydrid bestående afen monocyklisk eller bicyklisk ring, som indeholder 6-10 kulstofatomer ved fjernelse af et hydrogenatom, såsom phenyl eller naphthyl, som eventuelt kan substitueres af, men ikke begrænset til, Ci-6 alkyl, amino, halogen, -O(Ci-e alkyl), - OC(O)(Ci-e alkyl), -C(O)O(Ci-e alkyl), -NHC(O)(Ci-6 alkyl), -C(O)NH(Ci-6 alkyl), og -S(Ci-e alkyl) grupper; og hvor nævnte hudsygdomme og hudtilstande er valgt fra: rosacea, solforbrænding, kronisk solskade, diskret erytem, psoriasis, atopisk dermatitis, menopauseforbunden hedeture, hedeture som følge af orchiektomi-atopisk dermatitis, fotoældning, seborrhoisk dermatitis, akne, allergisk dermatitis, og irriteret dermatitis.
2. Sammensætning til anvendelse ifølge krav 1, hvor forbindelsen er som defineret af formel II, dets individuelle diastereoisomerer, dets hydrater, dets solvater, dets krystalformer, dets individuelle tautomerer eller et farmaceutisk acceptabelt salt deraf, O R2 R1 V Formel II hvor R1, R2, R3 og R er som defineret ovenfor.
3. Sammensætning til anvendelse ifølge krav 1, hvor forbindelsen er som defineret af formel III, dets individuelle diastereoisomerer, dets hydrater, dets solvater, dets krystalformer, dets individuelle tautomerer eller et farmaceutisk acceptabelt salt deraf,
O R2 R1 Nv> XR3 Formel III hvor R1, R2, R3 og R er som defineret ovenfor.
4. Sammensætning til anvendelse ifølge krav 2, hvor R1 er C1-3 alkyl, R2 er C1-3 alkyl, R3 er H og R er C1-10 alkyl.
5. Sammensætning til anvendelse ifølge krav 2, hvor R1 er methyl, R2 er methyl, R3 er H og R er C1-4 alkyl.
6. Sammensætning til anvendelse ifølge krav 2, hvor forbindelsen er valgt fra: iso-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2,2-Dimethyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; eddikesyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; benzoesyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
3-Methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
3-Phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
2-Amino-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 2-(2-Amino-3-methyl-butyrylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2-(2-Amino-acetylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; og
2- Amino-3-phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester.
7. Sammensætning til anvendelse ifølge krav 2, hvor forbindelsen er valgt fra: iso-smørsyre 3-[(S)-l-(l-iso-butyryl-lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 2,2-Dimethyl-propionsyre 3-{(S)-l-[l-(2,2-dimethyl-propionyl)-lH-imidazol-4-yl]-ethyl}-2-methyl-benzylester; eddikesyre 3-[(S)-l-(l-acetyl-lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; benzoesyre 3-[(S)-l-(l-benzoyl-lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
3- Methyl-smørsyre 2-methyl-3-{(S)-l-[l-(3-methyl-butyryl)-lH-imidazol- 4- yl]-ethyl}-benzylester; Phenyl-propionsyre 2-methyl-3-{(S)-l-[l-(3-phenyl-propionyl)-lH-imidazol-4-yl]-ethyl}-benzylester; 2-tert-Butoxycarbonylamino-3-methyl-smørsyre 3-{(S)-l-[l-(2-tert-butoxy carbonylamino-3-methyl-butyryl)-lH-imidazol-4-yl]-ethyl}-2-methyl-benzylester; 2-tert-Butoxycarbonylamino-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2-(2-tert-Butoxycarbonylamino-3-methyl-butyrylamino)-3-methyl-smørsyre 3-{(S)-l-[l-(2-tert-butoxycarbonylamino-3-methyl-butyryl)-lH-imidazol-4-yl]-ethyl}-2-methyl-benzylester; 2-(2-tert-Butoxycarbonylamino-3-methyl-butyrylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2-(2-tert-Butoxycarbonylamino-acetylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; og 2-tert-Butoxycarbonylamino-3-phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester.
8. Artikel til fremstilling omfattende indpakningsmateriale og et farmaceutisk middel indeholdt i nævnte indpakningsmateriale, hvor det farmaceutiske middel er terapeutisk effektiv til behandling af hudsygdomme og hudtilstande, og hvor indpakningsmaterialet omfatter et mærke, som indikerer, at det farmaceutiske middel kan anvendes til behandling af hudsygdomme og hudtilstande, og hvor nævnte farmaceutiske middel omfatter en effektiv mængde af en forbindelse valgt fra: iso-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2,2-Dimethyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; eddikesyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; benzoesyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
3-Methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
3-Phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
2-Amino-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 2-(2-Amino-3-methyl-butyrylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2-(2-Amino-acetylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; og
2-Amino-3-phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester.
9. Artikel til fremstilling omfattende indpakningsmateriale og et farmaceutisk middel indeholdt i nævnte indpakningsmateriale, hvor det farmaceutiske middel er terapeutisk effektiv til behandling af hudsygdomme og hudtilstande, og hvor indpakningsmaterialet omfatter et mærke, som indikerer, at det farmaceutiske middel kan anvendes til behandling af hudsygdomme og hudtilstande, og hvor nævnte farmaceutiske middel omfatter en effektiv mængde af en forbindelse valgt fra: iso-smørsyre 3-[(S)-l-(l-iso-butyryl-lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 2,2-Dimethyl-propionsyre 3-{(S)-l-[l-(2,2-dimethyl-propionyl)-lH-imidazol-4-yl]-ethyl}-2-methyl-benzylester; eddikesyre 3-[(S)-l-(l-acetyl-lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; benzoesyre 3-[(S)-l-(l-benzoyl-lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
3- Methyl-smørsyre 2-methyl-3-{(S)-l-[l-(3-methyl-butyryl)-lH-imidazol- 4- yl]-ethyl}-benzylester; Phenyl-propionsyre 2-methyl-3-{(S)-l-[l-(3-phenyl-propionyl)-lH-imidazol-4-yl]-ethyl}-benzylester; 2-tert-Butoxycarbonylamino-3-methyl-smørsyre 3-{(S)-l-[l-(2-tert-butoxy carbonylamino-3-methyl-butyryl)-lH-imidazol-4-yl]-ethyl}-2-methyl-benzylester; 2-tert-Butoxycarbonylamino-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2-(2-tert-Butoxycarbonylamino-3-methyl-butyrylamino)-3-methyl-smørsyre 3-{(S)-l-[l-(2-tert-butoxycarbonylamino-3-methyl-butyryl)-lH-imidazol-4-yl]-ethyl}-2-methyl-benzylester; 2-(2-tert-Butoxycarbonylamino-3-methyl-butyrylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2-(2-tert-Butoxycarbonylamino-acetylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; og 2-tert-Butoxycarbonylamino-3-phenyl-propionsyre 3-[(S)-l-(lH-imidazol- 4-yl)-ethyl]-2-methyl-benzylester.
10. Farmaceutisk sammensætning til behandling af hudsygdomme og hudtilstande hos en menneskelig patient omfattende en forbindelse med en struktur O R2 R1 R3 Formel II hvor R1, R2, R3 og R er som defineret ovenfor.
11. Den farmaceutiske sammensætning ifølge krav 10, hvor forbindelsen er valgt fra: iso-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2,2-Dimethyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; eddikesyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; benzoesyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
3-Methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
3-Phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
2-Amino-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 2-(2-Amino-3-methyl-butyrylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2-(2-Amino-acetylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; og
2-Amino-3-phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38337010P | 2010-09-16 | 2010-09-16 | |
EP11760961.0A EP2616067B1 (en) | 2010-09-16 | 2011-09-16 | Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]methanol for treating skin diseases and conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3050563T3 true DK3050563T3 (da) | 2018-08-13 |
Family
ID=44675870
Family Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16161922.6T DK3053576T3 (da) | 2010-09-16 | 2011-09-16 | Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk |
DK11760963.6T DK2616069T3 (da) | 2010-09-16 | 2011-09-16 | Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol |
DK16161920.0T DK3050563T3 (da) | 2010-09-16 | 2011-09-16 | Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af hudsygdomme og -tilstande |
DK18157147.2T DK3338777T3 (da) | 2010-09-16 | 2011-09-16 | Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af nethindesygdomme |
DK11760962.8T DK2616068T3 (da) | 2010-09-16 | 2011-09-16 | Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk |
DK18160174.1T DK3348264T3 (da) | 2010-09-16 | 2011-09-16 | Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk |
DK19194325.7T DK3636263T3 (da) | 2010-09-16 | 2011-09-16 | Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]-methanol |
DK16161923T DK3050564T3 (da) | 2010-09-16 | 2011-09-16 | Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]-methanol |
DK16161921.8T DK3078376T3 (da) | 2010-09-16 | 2011-09-16 | Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af nethindesygdomme |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16161922.6T DK3053576T3 (da) | 2010-09-16 | 2011-09-16 | Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk |
DK11760963.6T DK2616069T3 (da) | 2010-09-16 | 2011-09-16 | Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol |
Family Applications After (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18157147.2T DK3338777T3 (da) | 2010-09-16 | 2011-09-16 | Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af nethindesygdomme |
DK11760962.8T DK2616068T3 (da) | 2010-09-16 | 2011-09-16 | Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk |
DK18160174.1T DK3348264T3 (da) | 2010-09-16 | 2011-09-16 | Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk |
DK19194325.7T DK3636263T3 (da) | 2010-09-16 | 2011-09-16 | Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]-methanol |
DK16161923T DK3050564T3 (da) | 2010-09-16 | 2011-09-16 | Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]-methanol |
DK16161921.8T DK3078376T3 (da) | 2010-09-16 | 2011-09-16 | Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af nethindesygdomme |
Country Status (29)
Country | Link |
---|---|
US (9) | US8501796B2 (da) |
EP (13) | EP3053576B1 (da) |
JP (4) | JP2013541527A (da) |
KR (7) | KR102354097B1 (da) |
CN (5) | CN105412092B (da) |
AR (4) | AR083019A1 (da) |
AU (4) | AU2011301932C1 (da) |
BR (4) | BR112013006355A2 (da) |
CA (8) | CA2812197C (da) |
CL (4) | CL2013000736A1 (da) |
CY (3) | CY1121024T1 (da) |
DK (9) | DK3053576T3 (da) |
ES (10) | ES2904479T3 (da) |
HK (5) | HK1185538A1 (da) |
HU (5) | HUE049573T2 (da) |
IL (4) | IL225280A0 (da) |
MX (4) | MX2013003002A (da) |
MY (4) | MY191369A (da) |
NZ (1) | NZ608751A (da) |
PL (7) | PL3050563T3 (da) |
PT (7) | PT2616069T (da) |
RU (4) | RU2013116405A (da) |
SG (4) | SG188570A1 (da) |
SI (5) | SI3338777T1 (da) |
TR (1) | TR201909249T4 (da) |
TW (4) | TWI591058B (da) |
UA (1) | UA112973C2 (da) |
WO (4) | WO2012037499A1 (da) |
ZA (4) | ZA201302193B (da) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3566703T3 (da) * | 2009-02-13 | 2021-07-05 | Allergan Inc | Farmaceutiske sammensætninger omfattende (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol |
AU2011203867B2 (en) | 2010-01-11 | 2015-12-03 | Nalpropion Pharmaceuticals Llc | Methods of providing weight loss therapy in patients with major depression |
US8501796B2 (en) * | 2010-09-16 | 2013-08-06 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure |
BR112014001501A2 (pt) * | 2011-07-22 | 2017-02-14 | Allergan Inc | moduladores alfa-2 adrenérgicos para tratamento de distúrbios visuais mediados por projeções visuais centrais do olho |
WO2013078151A1 (en) | 2011-11-21 | 2013-05-30 | Allergan, Inc. | Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases |
USD794650S1 (en) | 2014-11-28 | 2017-08-15 | Samsung Electronics Co., Ltd. | Display screen or portion thereof with a graphical user interface |
CN108310442B (zh) * | 2017-01-17 | 2021-08-27 | 台北科技大学 | 眼科用组合物 |
KR102050506B1 (ko) | 2017-06-20 | 2019-11-29 | 한국식품연구원 | 망막 질환 예방, 개선, 완화 또는 치료용 조성물 |
CN108872431B (zh) * | 2018-07-09 | 2021-03-23 | 成都倍特药业股份有限公司 | 一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法 |
WO2020038387A1 (zh) * | 2018-08-24 | 2020-02-27 | 杭州阿诺生物医药科技有限公司 | 高活性sting蛋白激动剂 |
BR112023021140A2 (pt) * | 2021-04-16 | 2023-12-12 | Ads Therapeutics Llc | Cofármaco compreendendo uma fração de agonista muscarínico e uma fração de agonista alfa2 adrenérgico, ou um sal farmacêutico deste, composição farmacêutica e formulação farmacêutica |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3631490B2 (ja) | 1992-05-13 | 2005-03-23 | ノバルティス ファーマ株式会社 | シクロスポリン含有眼科用組成物 |
US5459133A (en) * | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
ES2188649T3 (es) | 1993-11-15 | 2003-07-01 | Schering Corp | Fenil-alquil-imidazoles como antagonistas del receptor h3. |
US5474979A (en) | 1994-05-17 | 1995-12-12 | Allergan, Inc. | Nonirritating emulsions for sensitive tissue |
EP0957073A1 (en) * | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
US20040214829A1 (en) * | 2000-07-14 | 2004-10-28 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
US20020198209A1 (en) | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
EP1638943B1 (fr) * | 2003-05-27 | 2008-08-06 | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) | NOUVEAUX DERIVES D’IMIDAZOLES, LEUR PREPARATION ET LEUR UTILISATION EN TANT QUE MEDICAMENT |
KR20060052809A (ko) * | 2003-07-14 | 2006-05-19 | 코닌클리케 필립스 일렉트로닉스 엔.브이. | 프로젝션 디바이스 |
WO2005034998A2 (en) * | 2003-09-12 | 2005-04-21 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
US20050059583A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
PL1761266T3 (pl) * | 2004-05-25 | 2013-09-30 | Galderma Pharma Sa | Związki, preparaty i sposoby leczenia lub zapobiegania procesom zapalnym skóry |
US20050277584A1 (en) | 2004-06-09 | 2005-12-15 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
EP1797043A1 (en) * | 2004-09-24 | 2007-06-20 | Allergan, Inc. | 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists |
US7931909B2 (en) | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
US7297679B2 (en) | 2005-07-13 | 2007-11-20 | Allergan, Inc. | Cyclosporin compositions |
US20070015691A1 (en) | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
US20070082070A1 (en) * | 2005-10-11 | 2007-04-12 | Stookey Evangeline L | Treating skin disorders |
US7902247B2 (en) | 2008-01-09 | 2011-03-08 | Allergan, Inc. | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
AU2010210513A1 (en) | 2009-02-06 | 2011-09-01 | Allergan, Inc. | Pyridine compounds as subtype selective modulators of alpha2B and/or alpha 2C adrenergic receptors |
DK3566703T3 (da) * | 2009-02-13 | 2021-07-05 | Allergan Inc | Farmaceutiske sammensætninger omfattende (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol |
US8394800B2 (en) * | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
US8501796B2 (en) * | 2010-09-16 | 2013-08-06 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure |
-
2011
- 2011-09-15 US US13/233,844 patent/US8501796B2/en active Active
- 2011-09-15 US US13/233,382 patent/US8653123B2/en active Active
- 2011-09-15 US US13/233,891 patent/US8492557B2/en active Active
- 2011-09-15 US US13/233,665 patent/US8492422B2/en active Active
- 2011-09-16 CA CA2812197A patent/CA2812197C/en active Active
- 2011-09-16 TW TW100133491A patent/TWI591058B/zh active
- 2011-09-16 EP EP16161922.6A patent/EP3053576B1/en active Active
- 2011-09-16 DK DK16161922.6T patent/DK3053576T3/da active
- 2011-09-16 CA CA3077732A patent/CA3077732A1/en active Pending
- 2011-09-16 MX MX2013003002A patent/MX2013003002A/es active IP Right Grant
- 2011-09-16 RU RU2013116405/15A patent/RU2013116405A/ru unknown
- 2011-09-16 AU AU2011301932A patent/AU2011301932C1/en active Active
- 2011-09-16 AR ARP110103391A patent/AR083019A1/es unknown
- 2011-09-16 TW TW100133488A patent/TW201240661A/zh unknown
- 2011-09-16 EP EP16161920.0A patent/EP3050563B1/en active Active
- 2011-09-16 PT PT117609636T patent/PT2616069T/pt unknown
- 2011-09-16 SI SI201131868T patent/SI3338777T1/sl unknown
- 2011-09-16 AR ARP110103390A patent/AR083018A1/es unknown
- 2011-09-16 HU HUE18160174A patent/HUE049573T2/hu unknown
- 2011-09-16 PL PL16161920T patent/PL3050563T3/pl unknown
- 2011-09-16 BR BR112013006355A patent/BR112013006355A2/pt not_active IP Right Cessation
- 2011-09-16 MY MYPI2013000930A patent/MY191369A/en unknown
- 2011-09-16 ES ES19194325T patent/ES2904479T3/es active Active
- 2011-09-16 SG SG2013019559A patent/SG188570A1/en unknown
- 2011-09-16 PL PL16161923T patent/PL3050564T3/pl unknown
- 2011-09-16 KR KR1020207021626A patent/KR102354097B1/ko active IP Right Grant
- 2011-09-16 MY MYPI2013000931A patent/MY168763A/en unknown
- 2011-09-16 SG SG2013019575A patent/SG188572A1/en unknown
- 2011-09-16 KR KR1020197004880A patent/KR102104760B1/ko active IP Right Grant
- 2011-09-16 BR BR112013006352A patent/BR112013006352A2/pt not_active IP Right Cessation
- 2011-09-16 KR KR1020137009503A patent/KR101840501B1/ko not_active Application Discontinuation
- 2011-09-16 EP EP11760958.6A patent/EP2616066B1/en active Active
- 2011-09-16 DK DK11760963.6T patent/DK2616069T3/da active
- 2011-09-16 DK DK16161920.0T patent/DK3050563T3/da active
- 2011-09-16 WO PCT/US2011/052004 patent/WO2012037499A1/en active Application Filing
- 2011-09-16 RU RU2013116403/15A patent/RU2013116403A/ru not_active Application Discontinuation
- 2011-09-16 NZ NZ60875111A patent/NZ608751A/en unknown
- 2011-09-16 EP EP11760963.6A patent/EP2616069B1/en active Active
- 2011-09-16 HU HUE16161922A patent/HUE039090T2/hu unknown
- 2011-09-16 WO PCT/US2011/051990 patent/WO2012037490A1/en active Application Filing
- 2011-09-16 BR BR112013006362A patent/BR112013006362A2/pt not_active IP Right Cessation
- 2011-09-16 HU HUE18157147A patent/HUE048725T2/hu unknown
- 2011-09-16 KR KR1020137009505A patent/KR20140005154A/ko not_active Application Discontinuation
- 2011-09-16 CN CN201510767798.7A patent/CN105412092B/zh active Active
- 2011-09-16 MX MX2013003004A patent/MX2013003004A/es active IP Right Grant
- 2011-09-16 SG SG2013019591A patent/SG188573A1/en unknown
- 2011-09-16 ES ES11760962.8T patent/ES2607084T3/es active Active
- 2011-09-16 EP EP19217499.3A patent/EP3698789A1/en not_active Withdrawn
- 2011-09-16 DK DK18157147.2T patent/DK3338777T3/da active
- 2011-09-16 PT PT161619234T patent/PT3050564T/pt unknown
- 2011-09-16 KR KR1020137009502A patent/KR101840500B1/ko active IP Right Grant
- 2011-09-16 AU AU2011301901A patent/AU2011301901B2/en active Active
- 2011-09-16 SG SG2013019567A patent/SG188571A1/en unknown
- 2011-09-16 RU RU2013116541A patent/RU2612351C2/ru active
- 2011-09-16 DK DK11760962.8T patent/DK2616068T3/da active
- 2011-09-16 UA UAA201304644A patent/UA112973C2/uk unknown
- 2011-09-16 CA CA2812195A patent/CA2812195A1/en not_active Abandoned
- 2011-09-16 EP EP16161923.4A patent/EP3050564B1/en active Active
- 2011-09-16 CA CA3116249A patent/CA3116249A1/en active Pending
- 2011-09-16 MY MYPI2013000932A patent/MY161607A/en unknown
- 2011-09-16 SI SI201131550T patent/SI3053576T1/sl unknown
- 2011-09-16 PL PL16161922T patent/PL3053576T3/pl unknown
- 2011-09-16 JP JP2013529360A patent/JP2013541527A/ja not_active Withdrawn
- 2011-09-16 PT PT16161922T patent/PT3053576T/pt unknown
- 2011-09-16 AU AU2011301847A patent/AU2011301847B2/en active Active
- 2011-09-16 PL PL18157147T patent/PL3338777T3/pl unknown
- 2011-09-16 PT PT117609628T patent/PT2616068T/pt unknown
- 2011-09-16 PT PT181601741T patent/PT3348264T/pt unknown
- 2011-09-16 ES ES18157147T patent/ES2788051T3/es active Active
- 2011-09-16 EP EP16161921.8A patent/EP3078376B1/en active Active
- 2011-09-16 CA CA3122745A patent/CA3122745A1/en active Pending
- 2011-09-16 SI SI201131819T patent/SI3050564T1/sl unknown
- 2011-09-16 PT PT181571472T patent/PT3338777T/pt unknown
- 2011-09-16 EP EP18157147.2A patent/EP3338777B1/en active Active
- 2011-09-16 ES ES16161920.0T patent/ES2687420T3/es active Active
- 2011-09-16 WO PCT/US2011/051979 patent/WO2012037484A1/en active Application Filing
- 2011-09-16 CA CA3079450A patent/CA3079450A1/en active Pending
- 2011-09-16 PL PL18160174T patent/PL3348264T3/pl unknown
- 2011-09-16 CN CN2011800546049A patent/CN103209694A/zh active Pending
- 2011-09-16 JP JP2013529371A patent/JP2013537236A/ja not_active Withdrawn
- 2011-09-16 CA CA2811559A patent/CA2811559A1/en active Pending
- 2011-09-16 ES ES18160174T patent/ES2781681T3/es active Active
- 2011-09-16 JP JP2013529373A patent/JP6073229B2/ja active Active
- 2011-09-16 DK DK18160174.1T patent/DK3348264T3/da active
- 2011-09-16 PL PL11760963T patent/PL2616069T3/pl unknown
- 2011-09-16 JP JP2013529372A patent/JP6045495B2/ja active Active
- 2011-09-16 HU HUE16161920A patent/HUE038698T2/hu unknown
- 2011-09-16 ES ES16161921T patent/ES2737230T3/es active Active
- 2011-09-16 RU RU2013116763/15A patent/RU2013116763A/ru not_active Application Discontinuation
- 2011-09-16 PT PT16161920T patent/PT3050563T/pt unknown
- 2011-09-16 ES ES11760963.6T patent/ES2613509T3/es active Active
- 2011-09-16 DK DK19194325.7T patent/DK3636263T3/da active
- 2011-09-16 KR KR1020137009506A patent/KR101952457B1/ko active IP Right Grant
- 2011-09-16 MX MX2013003008A patent/MX2013003008A/es active IP Right Grant
- 2011-09-16 EP EP19194325.7A patent/EP3636263B1/en active Active
- 2011-09-16 TW TW100133487A patent/TW201305116A/zh unknown
- 2011-09-16 CN CN201180053886.0A patent/CN103200941B/zh active Active
- 2011-09-16 DK DK16161923T patent/DK3050564T3/da active
- 2011-09-16 MY MYPI2013000907A patent/MY173846A/en unknown
- 2011-09-16 ES ES11760958.6T patent/ES2593612T3/es active Active
- 2011-09-16 TW TW100133498A patent/TW201240662A/zh unknown
- 2011-09-16 EP EP11760962.8A patent/EP2616068B1/en active Active
- 2011-09-16 EP EP11760961.0A patent/EP2616067B1/en active Active
- 2011-09-16 MX MX2013003009A patent/MX2013003009A/es active IP Right Grant
- 2011-09-16 AR ARP110103389A patent/AR083017A1/es not_active Application Discontinuation
- 2011-09-16 TR TR2019/09249T patent/TR201909249T4/tr unknown
- 2011-09-16 WO PCT/US2011/051926 patent/WO2012037453A1/en active Application Filing
- 2011-09-16 ES ES16161923T patent/ES2760920T3/es active Active
- 2011-09-16 CN CN201180053895XA patent/CN103200942A/zh active Pending
- 2011-09-16 AU AU2011301856A patent/AU2011301856C1/en active Active
- 2011-09-16 AR ARP110103392A patent/AR083020A1/es unknown
- 2011-09-16 SI SI201131547T patent/SI3050563T1/sl unknown
- 2011-09-16 KR KR1020207011231A patent/KR102139905B1/ko active Application Filing
- 2011-09-16 EP EP20153104.3A patent/EP3659600A1/en not_active Withdrawn
- 2011-09-16 SI SI201131857T patent/SI3348264T1/sl unknown
- 2011-09-16 DK DK16161921.8T patent/DK3078376T3/da active
- 2011-09-16 CN CN2011800545690A patent/CN103221045A/zh active Pending
- 2011-09-16 HU HUE16161923A patent/HUE047476T2/hu unknown
- 2011-09-16 PL PL11760962.8T patent/PL2616068T3/pl unknown
- 2011-09-16 CA CA2812191A patent/CA2812191C/en active Active
- 2011-09-16 ES ES16161922.6T patent/ES2684055T3/es active Active
- 2011-09-16 EP EP18160174.1A patent/EP3348264B1/en active Active
- 2011-09-16 BR BR112013006320-3A patent/BR112013006320B1/pt active IP Right Grant
-
2013
- 2013-03-17 IL IL225280A patent/IL225280A0/en active IP Right Grant
- 2013-03-17 IL IL225281A patent/IL225281A0/en unknown
- 2013-03-17 IL IL225282A patent/IL225282A0/en unknown
- 2013-03-17 IL IL225278A patent/IL225278A/en active IP Right Grant
- 2013-03-18 CL CL2013000736A patent/CL2013000736A1/es unknown
- 2013-03-18 CL CL2013000733A patent/CL2013000733A1/es unknown
- 2013-03-18 CL CL2013000735A patent/CL2013000735A1/es unknown
- 2013-03-18 CL CL2013000734A patent/CL2013000734A1/es unknown
- 2013-03-25 ZA ZA2013/02193A patent/ZA201302193B/en unknown
- 2013-03-25 ZA ZA2013/02194A patent/ZA201302194B/en unknown
- 2013-03-27 ZA ZA2013/02291A patent/ZA201302291B/en unknown
- 2013-03-27 ZA ZA2013/02288A patent/ZA201302288B/en unknown
- 2013-06-13 US US13/916,888 patent/US20130289088A1/en not_active Abandoned
- 2013-06-24 US US13/925,502 patent/US20130296394A1/en not_active Abandoned
- 2013-11-04 US US14/071,090 patent/US8853251B2/en active Active
- 2013-11-19 HK HK13112917.0A patent/HK1185538A1/zh unknown
- 2013-11-19 HK HK13112925.0A patent/HK1185541A1/zh unknown
- 2013-11-19 HK HK13112920.5A patent/HK1185540A1/zh unknown
- 2013-11-19 HK HK13112919.8A patent/HK1185539A1/zh unknown
-
2015
- 2015-01-29 US US14/608,458 patent/US20150148394A1/en not_active Abandoned
-
2016
- 2016-08-18 US US15/240,219 patent/US20160354346A1/en not_active Abandoned
-
2018
- 2018-08-13 CY CY181100852T patent/CY1121024T1/el unknown
- 2018-12-27 HK HK18116626.8A patent/HK1257416A1/zh unknown
-
2020
- 2020-03-20 CY CY20201100265T patent/CY1122958T1/el unknown
- 2020-04-21 CY CY20201100365T patent/CY1122809T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3050563T3 (da) | Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af hudsygdomme og -tilstande | |
AU2011301856B2 (en) | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol |